Showing results 1 to 3 of 3
Title | Author(s) | Issue Date | |
---|---|---|---|
AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology International | 2021 | ||
Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | ||
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology | 2021 |